## Mario Rizzetto

## List of Publications by Citations

Source: https://exaly.com/author-pdf/8476119/mario-rizzetto-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123 3,313 32 55 h-index g-index citations papers 6.9 3,906 5.58 139 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
123	The delta agent. <i>Hepatology</i> , <b>1983</b> , 3, 729-37	11.2	319
122	Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. <i>Annals of Internal Medicine</i> , <b>1983</b> , 98, 437-41	8	272
121	Chronic hepatitis D: a vanishing Disease? An Italian multicenter study. <i>Hepatology</i> , <b>2000</b> , 32, 824-7	11.2	182
120	Hepatitis D: thirty years after. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 1043-50	13.4	174
119	Patterns of hepatitis delta virus reinfection and disease in liver transplantation. <i>Gastroenterology</i> , <b>1991</b> , 101, 1649-55	13.3	125
118	A randomized controlled trial of a 12-month course of recombinant human interferon-lin chronic delta (type D) hepatitis: A multicenter Italian study. <i>Hepatology</i> , <b>1991</b> , 13, 1052-1056	11.2	108
117	Epidemiologic patterns of infection with the hepatitis B virus-associated delta agent in Italy. <i>American Journal of Epidemiology</i> , <b>1983</b> , 117, 223-9	3.8	100
116	Changing pattern of chronic hepatitis D in Southern Europe. <i>Gastroenterology</i> , <b>1999</b> , 117, 161-6	13.3	97
115	Outcome of chronic delta hepatitis in Italy: a long-term cohort study. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 834-40	13.4	89
114	Hepatitis D Virus: Introduction and Epidemiology. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2015</b> , 5, a021576	5.4	86
113	Epidemiology of hepatitis D. Seminars in Liver Disease, <b>2012</b> , 32, 211-9	7.3	74
112	Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2005</b> , 42, 173-9	13.4	70
111	A histological study of hepatitis delta virus liver disease. <i>Hepatology</i> , <b>1986</b> , 6, 1303-7	11.2	70
110	Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 301-307	13.4	69
109	Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. <i>Lipids</i> , <b>2001</b> , 36, 1117-24	1.6	68
108	Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. <i>Journal of Medical Virology</i> , <b>2018</b> , 90, 320-327	19.7	57
107	Clinical significance of antibody to the hepatitis delta virus in symptomless HBsAg carriers. <i>Lancet, The,</i> <b>1985</b> , 2, 356-8	40	57

## (2002-2015)

106	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 41-7	7 <sup>13.4</sup>	54	
105	Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 53, 79-84	3.9	52	
104	The epidemiology of hepatitis delta infection in Italy. Promoting Group. <i>Journal of Hepatology</i> , <b>1992</b> , 15, 211-5	13.4	48	
103	The adventure of delta. <i>Liver International</i> , <b>2016</b> , 36 Suppl 1, 135-40	7.9	45	
102	Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2016</b> , 63, 107-16	11.2	42	
101	Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). <i>Liver International</i> , <b>2018</b> , 38, 842-850	7.9	41	
100	Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. Journal of Medical Virology, 2002, 66, 435-	<b>45</b> 917	40	
99	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 1008-1015	13.4	40	
98	Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection. <i>Hepatology Research</i> , <b>2016</b> , 46, E130-5	5.1	38	
97	Hepatitis delta: the rediscovery. <i>Clinics in Liver Disease</i> , <b>2013</b> , 17, 475-87	4.6	38	
96	Chronic HBV-related liver disease. <i>Molecular Aspects of Medicine</i> , <b>2008</b> , 29, 72-84	16.7	38	
95	Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. <i>Gastroenterology</i> , <b>2014</b> , 146, 744-753.e3	13.3	37	
94	Familiar clustering and spreading of hepatitis delta virus infection. <i>Journal of Hepatology</i> , <b>1985</b> , 1, 221-6	513.4	37	
93	Chronic hepatitis D at a standstill: where do we go from here?. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2014</b> , 11, 68-71	24.2	35	
92	Prevalence of hepatitis d in the eastern mediterranean region: systematic review and meta analysis. <i>Hepatitis Monthly</i> , <b>2013</b> , 13, e8210	1.8	34	
91	Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation. <i>Hepatology</i> , <b>1998</b> , 27, 873-6	11.2	31	
90	HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 1254-8	13.4	29	
89	Spectral electroencephalogram analysis in hepatic encephalopathy and liver transplantation. <i>Liver Transplantation</i> , <b>2002</b> , 8, 630-5	4.5	27	

88	Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. <i>Panminerva Medica</i> , <b>2017</b> , 59, 283-289	2	26
87	The changing context of hepatitis D. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1200-1211	13.4	24
86	UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2014</b> , 98, 271-8	3.5	21
85	Hepatitis D: clinical features and therapy. <i>Digestive Diseases</i> , <b>2010</b> , 28, 139-43	3.2	21
84	Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: correlation with the ARCHITECT quantitative assays. <i>Journal of Clinical Virology</i> , <b>2014</b> , 60, 341-6	14.5	19
83	IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 13146-52	5.6	19
82	Hepatitis D: the comeback?. <i>Liver International</i> , <b>2009</b> , 29 Suppl 1, 140-2	7.9	18
81	Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-[]Hepatology Research, 2017, 47, 747-754	5.1	17
80	HDV: thirty years later. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43 Suppl 1, S15-8	3.3	17
79	Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 55-61	3.3	16
78	Targeting Hepatitis D. Seminars in Liver Disease, 2018, 38, 66-72	7.3	14
77	Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8 T Cells. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	14
76	Multiple courses of G-CSF in patients with decompensated cirrhosis: consistent mobilization of immature cells expressing hepatocyte markers and exploratory clinical evaluation. <i>Hepatology International</i> , <b>2013</b> , 7, 1075-83	8.8	14
75	Current management of delta hepatitis. <i>Liver International</i> , <b>2013</b> , 33 Suppl 1, 195-7	7.9	14
74	Treatment of hepatitis B e antigen-negative chronic hepatitis B with lamivudine. <i>Journal of Hepatology</i> , <b>2003</b> , 39 Suppl 1, S168-71	13.4	13
73	ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. <i>Biomedicine and Pharmacotherapy</i> , <b>2015</b> , 69, 63-9	7.5	12
72	Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. <i>Antiviral Research</i> , <b>2014</b> , 109, 7-14	10.8	12
71	Posttransplantation prevention and treatment of recurrent hepatitis B. <i>Liver Transplantation</i> , <b>2000</b> , 6, S47-51	4.5	12

70	Pegylated interferon [blus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 826-32	3.3	11
69	Narrow band imaging vs. high definition colonoscopy for detection of colorectal adenomas in patients with positive faecal occult blood test: a randomised trial. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 803-7	3.3	11
68	Endoscopic ultrasound in common bile duct dilatation with normal liver enzymes. <i>World Journal of Gastrointestinal Endoscopy</i> , <b>2015</b> , 7, 799-805	2.2	11
67	Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ReRantigen-negative chronic hepatitis B genotype D. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 118-	1 <sup>2</sup> 2 <sup>4</sup> 5	11
66	The prenylation inhibitor, lonafarnib: a new therapeutic strategy against hepatitis delta. <i>Lancet Infectious Diseases, The</i> , <b>2015</b> , 15, 1119-1120	25.5	10
65	A randomized controlled trial of a 12-month course of recombinant human interferon-lin chronic delta (type D) hepatitis: A multicenter Italian study <b>1991</b> , 13, 1052		10
64	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. <i>Minerva Medica</i> , <b>2019</b> , 110, 401-409	2.2	9
63	The medical impact of hepatitis D virus infection in Uzbekistan. <i>Liver International</i> , <b>2019</b> , 39, 2077-2081	7.9	8
62	Chronic Hepatitis D; at a Standstill?. <i>Digestive Diseases</i> , <b>2016</b> , 34, 303-7	3.2	8
61	Antiplatelet and anticoagulant drugs management before gastrointestinal endoscopy: do clinicians adhere to current guidelines?. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 45-9	3.3	7
60	Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2020</b> , 96, 114985	2.9	7
59	Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. Journal of Medical Virology, 2002, 66, 435-	· <b>51</b> 9.7	7
58	Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 405-	1 <del>0</del> 3	6
57	Investigational drugs in development for Hepatitis D. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 999-1005	5.9	6
56	Drug-Induced Liver Injury1209-1268		6
55	Management of hepatitis D virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1991</b> , 6 Suppl 1, 23-5	4	6
54	Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia. <i>BMJ Open Gastroenterology</i> , <b>2016</b> , 3, e000119	3.9	5
53	Prospective randomized trial: endoscopic follow up 3 vs 6 months after esophageal variceal eradication by band ligation in cirrhosis. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 674-9	3.9	5

52	Progress in the prevention and control of viral hepatitis type B: closing remarks. <i>Journal of Medical Virology</i> , <b>2002</b> , 67, 463-6	19.7	5
51	Clinical and Diagnostic Aspects of Cirrhosis604-619		5
50	Adrenal function and microbial DNA in noninfected cirrhotic patients with ascites: Relationship and effect on survival. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 702-8	3.3	4
49	2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 583-605	6.1	4
48	Endpoints and New Options for Treatment of Chronic Hepatitis D. <i>Hepatology</i> , <b>2021</b> , 74, 3479-3485	11.2	4
47	Biochemical Investigations in the Management of Liver Disease451-467		4
46	Hepatic Removal Kinetics: Importance for Quantitative Measurements of Liver Function468-478		4
45	Efficacy of lamivudine in HBeAg-negative chronic hepatitis B <b>2002</b> , 66, 435		4
44	Hepatitis D Virus <b>2019</b> , 135-148		3
43	Treatment of hepatitis B virus cirrhosis. <i>Hepatitis Monthly</i> , <b>2012</b> , 12, 309-11	1.8	2
43	Treatment of hepatitis B virus cirrhosis. <i>Hepatitis Monthly</i> , <b>2012</b> , 12, 309-11  Normal lymphocyte interferon production in adult HBsAg-positive chronic active liver disease. <i>Journal of Medical Virology</i> , <b>1979</b> , 4, 43-50	1.8	2
	Normal lymphocyte interferon production in adult HBsAg-positive chronic active liver disease.		
42	Normal lymphocyte interferon production in adult HBsAg-positive chronic active liver disease. Journal of Medical Virology, <b>1979</b> , 4, 43-50		2
42 41	Normal lymphocyte interferon production in adult HBsAg-positive chronic active liver disease.  Journal of Medical Virology, 1979, 4, 43-50  Non-Alcoholic Fatty Liver and Non-Alcoholic Steatohepatitis1193-1208  The Discovery of the Hepatitis D Virus: Three Princes of Serendip and the Recognition of	2.2	2
4 <sup>2</sup> 41 40	Normal lymphocyte interferon production in adult HBsAg-positive chronic active liver disease. <i>Journal of Medical Virology</i> , <b>1979</b> , 4, 43-50  Non-Alcoholic Fatty Liver and Non-Alcoholic Steatohepatitis1193-1208  The Discovery of the Hepatitis D Virus: Three Princes of Serendip and the Recognition of Autoantibodies to Liver-Kidney Microsomes. <i>Clinical Liver Disease</i> , <b>2020</b> , 16, 1-11  Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors. <i>Journal of Hepatology</i> , <b>2019</b> ,	2.2	2 2
42 41 40 39	Normal lymphocyte interferon production in adult HBsAg-positive chronic active liver disease. <i>Journal of Medical Virology</i> , <b>1979</b> , 4, 43-50  Non-Alcoholic Fatty Liver and Non-Alcoholic Steatohepatitis1193-1208  The Discovery of the Hepatitis D Virus: Three Princes of Serendip and the Recognition of Autoantibodies to Liver-Kidney Microsomes. <i>Clinical Liver Disease</i> , <b>2020</b> , 16, 1-11  Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 793-795  The medical impact of hepatitis D virus infection in Asia and Africa; time for a reappraisal. <i>Liver</i>	19.7 2.2 13.4	2 2 2
42 41 40 39 38	Normal lymphocyte interferon production in adult HBsAg-positive chronic active liver disease. <i>Journal of Medical Virology</i> , <b>1979</b> , 4, 43-50  Non-Alcoholic Fatty Liver and Non-Alcoholic Steatohepatitis1193-1208  The Discovery of the Hepatitis D Virus: Three Princes of Serendip and the Recognition of Autoantibodies to Liver-Kidney Microsomes. <i>Clinical Liver Disease</i> , <b>2020</b> , 16, 1-11  Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 793-795  The medical impact of hepatitis D virus infection in Asia and Africa; time for a reappraisal. <i>Liver International</i> , <b>2021</b> , 41, 16-19	19.7 2.2 13.4	2 2 2 2

34	Hepatitis D(delta). Seminars in Liver Disease, 2012, 32, 193-4	7.3	1
33	Delta Hepatitis: Forgotten, but Not Gone. Current Hepatitis Reports, <b>2010</b> , 9, 239-242		1
32	Pathogenesis, Diagnosis and Treatment of Ascites in Cirrhosis666-710		1
31	Liver and Biliary Tract Histology9-19		1
30	Prescribing Drugs in Liver Disease1912-1921		1
29	The Evolution of Cirrhosis581-589		1
28	Intrahepatic Cholestasis1479-1500		1
27	Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	1
26	Fungal Infections Affecting the Liver1011-1019		1
25	Pathology of Alcoholic Liver Disease1148-1156		1
24	Alcoholic Liver Disease: Natural History, Diagnosis, Clinical Features, Evaluation, Prognosis and Manag	ement	11 <u>Б</u> 7-1178
23	Obstruction of the Portal Vein1395-1402		1
22	Malignant Tumours1437-1463		1
21	Ultrastructure of the Hepatocyte20-28		1
20	The Liver in Cardiovascular Disease1607-1615		1
19	The Effect of Gastrointestinal Diseases on the Liver and Biliary Tract1622-1633		1
18	The Effect of Haematological and Lymphatic Diseases on the Liver1662-1670		1
17	The Liver in Graft-vsHost Disease1671-1679		1

16	Musculoskeletal Diseases and the Liver1694-1701		1
15	Development of the Liver Interactome: Mapping the Regulatory Networks2088-2095		О
14	The Liver in Lung Diseases1616-1621		О
13	The Liver in Urogenital Diseases1653-1661		О
12	Human Immunodeficiency Virus and the Liver974-987		О
11	Total Parenteral Nutrition-Related Liver Disease1634-1641		О
10	Haematological Abnormalities in Liver Disease1767-1779		О
9	Haemostasis in Liver Disease1780-1797		О
8	The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. <i>Journal of Advanced Research</i> , <b>2021</b> , 33, 183-187	13	О
7	Imaging of the Liver500-548		
6	Liver Sinusoidal Endothelial Cells29-35		
5	Macroscopic Anatomy of the Liver1-8		
4	Liver Injury in Man Ascribed to Non-Drug Chemicals and Natural Toxins2105-2121		
3	Biliary Epithelial Cells52-57		
2	Hepatitis D <b>2016</b> , 1409-1423		
1	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with		